华法林相关急性消化道出血抗凝逆转策略的比较
该回顾性分析纳入815例华法林相关消化道出血的急诊患者,比较就诊12小时内使用PCC、FFP、单用维生素K或未逆转的情况。主要终点30天全因死亡率在PCC组为18.4%,显著高于FFP组5.7%、维生素K组4.6%和未逆转组5.6%(p<0.001),校正血流动力学不稳定和ICU入住后仍显著。30天血栓事件率各组无显著差异(3.4% vs 3.8% vs 1.4% vs 1.2%,p=0.20)。作者认为需进一步研究解释PCC组死亡率增高的原因。
要点
- 在815例华法林相关消化道出血患者中,12小时内接受PCC逆转者30天死亡率为18.4%,显著高于FFP组5.7%、维生素K组4.6%和未逆转组5.6%(p<0.001)。
- 校正血流动力学不稳定和ICU入住后,PCC组30天死亡率仍显著高于其他组。
- 30天血栓事件率各组无显著差异:PCC组3.4%、FFP组3.8%、维生素K组1.4%、未逆转组1.2%(p=0.20)。
- 作者认为需进一步研究以理解PCC组死亡率差异的原因。
适用人群与场景
- 急诊科华法林相关消化道出血患者。
研究设计与关键结果
- 回顾性分析纳入815例华法林相关消化道出血的急诊患者。
- 就诊12小时内,10.7%接受PCC(联合或不联合维生素K)逆转,12.9%接受FFP(联合或不联合维生素K),34.9%单用维生素K,41.5%未接受逆转剂。
- 主要终点30天全因死亡率:PCC组18.4% vs FFP组5.7% vs 维生素K组4.6% vs 未逆转组5.6%(p<0.001)。
- 校正血流动力学不稳定和ICU入住后,PCC组30天死亡率仍显著高于其他组。
- 30天血栓事件率:PCC组3.4% vs FFP组3.8% vs 维生素K组1.4% vs 未逆转组1.2%(p=0.20),无显著差异。
证据类型、等级与局限
- 证据类型:回顾性分析,遵循STROBE报告规范。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,需进一步研究以理解华法林相关消化道出血患者中PCC组死亡率差异的原因。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Gastrointestinal bleeding (GIB) is a common complication associated with warfarin use. However, the optimal approach for anticoagulation reversal-whether with prothrombin complex concentrate (PCC), fresh frozen plasma (FFP), vitamin K (intravenous or oral), or no reversal-remains unclear as current literature and society guidelines do not provide definitive recommendations.
METHODS: A retrospective analysis of emergency department patients with warfarin-associated GIB who presented to an academic health system was performed, comparing reversal with PCC, FFP, vitamin K only, or no reversal agent. The primary outcome was 30-day all-cause mortality. Secondary outcomes included rebleeding events and 30-day thrombotic events. Standardized guidelines for reporting were followed (STROBE).
RESULTS: Of 815 patients, within 12 h of presentation, 10.7 % received reversal with PCC (with or without vitamin K), 12.9 % with FFP (with or without vitamin K), and 34.9 % with vitamin K alone; 41.5 % of patients received no reversal agent. Compared to all other groups, patients receiving PCC had significantly higher 30-day mortality (18.4 % [PCC] vs 5.7 % [FFP] vs 4.6 % [vitamin K] vs 5.6 % [no reversal], p < 0.001), which remained significant after adjusting for hemodynamic instability and ICU admission. There were no significant differences in rates of thrombotic event within 30 days (3.4 % vs 3.8 % vs 1.4 % vs 1.2 %, p = 0.20).
CONCLUSIONS: Patients who received PCC had a threefold increase in mortality compared to FFP, vitamin K alone, or no reversal, even after adjusting for severity of the bleeding. Further research is necessary to understand factors leading to this observed mortality difference among patients with warfarin related GIB.
参考来源
- Hess KA, Mattson AE, Bellolio F, et al. Comparison of anticoagulation reversal strategies for warfarin associated acute gastrointestinal bleeding. Am J Emerg Med. 2025. PMID: 40273639. doi:10.1016/j.ajem.2025.04.029
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。